Susceptibility of Legionella pneumophila to ofloxacin in vitro and in experimental Legionella pneumonia in guinea pigs.
about
In vitro and in vivo antibacterial activity of AM-833, a new quinolone derivativeComparative in vitro activity of WIN 57273, a new fluoroquinolone antimicrobial agentIn vitro and in vivo antibacterial activities of BMY 40062, a new fluoronaphthyridoneEvaluation of quinolones in experimental animal models of infections.In vitro activities of fleroxacin against clinical isolates of Legionella spp., its pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumoniaComparative activities of piperacillin and tazobactam against clinical isolates of Legionella spp.Preparation and evaluation of ofloxacin-loaded palmitic acid solid lipid nanoparticles.Legionnaires disease: historical perspectiveLaboratory diagnosis of infections caused by legionellae.Ofloxacin: its pharmacology, pharmacokinetics, and potential for clinical application.Quinolones in the treatment of lower respiratory tract infections caused by intracellular pathogens.Activity of trovafloxacin (CP-99,219) against Legionella isolates: in vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumoniaComparative postantibacterial activities of pefloxacin, ciprofloxacin, and ofloxacin against intracellular multiplication of Legionella pneumophila serogroup 1In vitro activity of sparfloxacin (CI-978; AT-4140) for clinical Legionella isolates, pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia.WIN 57273 is bactericidal for Legionella pneumophila grown in alveolar macrophagesComparative evaluation of enoxacin, ofloxacin, ampicillin, and chloramphenicol for treatment of experimental Haemophilus influenzae pneumonia.Effect of quinolones and other antimicrobial agents on cell-associated Legionella pneumophilaInhibition of Legionella pneumophila multiplication within human macrophages by antimicrobial agents.In vitro and in vivo antibacterial activities of T-3761, a new quinolone derivative.In vitro activities of BAY Y3118, ciprofloxacin, ofloxacin, and fleroxacin against gram-positive and gram-negative pathogens from respiratory tract and soft tissue infections.Comparison of charcoal- and starch-based media for testing susceptibilities of Legionella species to macrolides, azalides, and fluoroquinolones.Activity of temafloxacin against respiratory pathogens.Legionellosis in Transplantation.Simplified quantitative assay system for measuring activities of drugs against intracellular Legionella pneumophila.Susceptibilities of Legionella spp. to newer antimicrobials in vitro.Subinhibitory concentrations of antimicrobial agents reduce the uptake of Legionella pneumophila into Acanthamoeba castellanii and U937 cells by altering the expression of virulence-associated antigens.Mode of action, and in vitro and in vivo activities of the fluoroquinolones.Intracellular activity of tosufloxacin (T-3262) against Salmonella enteritidis and ability to penetrate into tissue culture cells of human origin.Fluorometric measurement of ofloxacin uptake by human polymorphonuclear leukocytes.Inhibition of theophylline clearance by coadministered ofloxacin without alteration of theophylline effects.Comparative in vitro activity of CGP 31608, a new penem antibioticHigh-performance liquid chromatography measurement of antimicrobial concentrations in polymorphonuclear leukocytes.Efficacy of NY-198 against experimental Legionnaires disease.Comparative evaluation of ciprofloxacin, enoxacin, and ofloxacin in experimental Pseudomonas aeruginosa pneumonia.Accumulation of a newly developed fluoroquinolone, OPC-17116, by human polymorphonuclear leukocytes.Rifampin resistance of Legionella pneumophila is not increased during therapy for experimental Legionnaires disease: study of rifampin resistance using a guinea pig model of Legionnaires disease.Evaluation of a human monocytic cell line THP-1 model for assay of the intracellular activities of antimicrobial agents against Legionella pneumophila.The association of antibiotic treatment regimen and hospital mortality in patients hospitalized with Legionella pneumonia.Multiresistant waterborne pathogens isolated from water reservoirs and cooling systems.Antimicrobial activity of ten macrolide, lincosamine and streptogramin drugs tested against Legionella species.
P2860
Q24685742-C4BE66FA-5F4F-43C5-BF9C-0C56FF65D779Q28335923-574B1D7A-7657-482D-9B8C-9B6F4259CF7EQ28359405-6FAC52A1-EF63-4D40-8D82-11D8EF1DE82CQ30446615-6B3DACC0-0642-4000-A338-1A6275F5C25CQ33744843-D6C1C59A-57F9-4F35-B29B-0B4F17EFD076Q33747823-063AF03B-0893-4691-97BD-E8B072AFE492Q33863671-56E735C5-CD4D-40D4-972F-9A47D98A2D7CQ34164604-5A064830-3B6F-4B5A-948D-F3286AD514DDQ34183542-CB85E42E-D55D-427C-B5A5-2192D43B1EF7Q34687048-E1070B9C-2BF5-46C8-B9FA-2CBD96E08A32Q34719806-DF456A5B-58DF-4BC8-906E-2D03195EEBCDQ35122254-42922DA2-B77A-4316-AD2E-CA13ACB95A35Q35272717-F5BCF939-ECBB-4D00-87EC-691F37CF8507Q35280841-FB4A42A7-F1BA-4E7B-B697-5211CAA63C68Q35364046-57746547-1C0B-4520-95BA-A1B501043A44Q35537723-54874415-2EA7-4E6D-844F-F2068FB96A08Q35542379-7001D6FE-3F3A-48D5-9572-5631D32BE84FQ35575694-8BE287E3-B945-4BC4-9956-00B43FD48BAAQ35809707-ED6E1295-463A-48AB-BA2C-977594BD49F6Q35819848-7DC0B725-11DE-40CB-924A-C294931B8299Q36547774-4638CA68-16E9-425F-82BD-84E21F25C39AQ36753020-2EF18B21-8DBD-4D07-AB6D-BED434C90EB8Q38726663-0E87E257-5F48-4288-844B-567D8C80BC28Q39553788-05E0A2BD-F7C9-4935-BD2A-408832152EBBQ39557831-9A8A7F0B-708A-4644-966B-AA5AF28E5387Q39559397-0A533872-5ACF-41B8-9140-1731B08C9959Q39637667-B16BFC51-0820-43FC-9892-052BC0A94F88Q39816058-30C63D47-B17B-4515-95F9-C018F1FE39C9Q39819180-4BB2F8FF-01F0-480B-A260-7682A78C58CFQ39827802-C7C9DD1A-0767-4E66-B2C0-38C64FBD3953Q39828520-1C3BEFF8-C90F-4BB5-BAB6-EE2626E06BE0Q39832110-77D9BC00-ACBA-42AB-A3A4-8F9364702CD7Q39832353-5A45DA26-6B19-4315-96BB-C690B00372DFQ39850865-47FE676F-F030-4D86-A3CE-EF7F14C71DC2Q39866608-53FE01FB-7870-4666-904B-01059A302C0EQ40085510-218E9336-7FA3-4AE3-968C-20494E53C6C0Q40851098-BC879646-443C-47C7-8A14-52F1BFB95FC6Q41461523-E64BA4EC-365D-4598-B375-DFA327AD9405Q47890331-3F2FB7DB-2C59-4C7A-AE06-A1D1C15558EFQ54265235-A98A01CF-2C21-48EC-BA09-53DF2260FE46
P2860
Susceptibility of Legionella pneumophila to ofloxacin in vitro and in experimental Legionella pneumonia in guinea pigs.
description
1985 nî lūn-bûn
@nan
1985年の論文
@ja
1985年学术文章
@wuu
1985年学术文章
@zh-cn
1985年学术文章
@zh-hans
1985年学术文章
@zh-my
1985年学术文章
@zh-sg
1985年學術文章
@yue
1985年學術文章
@zh
1985年學術文章
@zh-hant
name
Susceptibility of Legionella p ...... ella pneumonia in guinea pigs.
@en
Susceptibility of Legionella p ...... ella pneumonia in guinea pigs.
@nl
type
label
Susceptibility of Legionella p ...... ella pneumonia in guinea pigs.
@en
Susceptibility of Legionella p ...... ella pneumonia in guinea pigs.
@nl
prefLabel
Susceptibility of Legionella p ...... ella pneumonia in guinea pigs.
@en
Susceptibility of Legionella p ...... ella pneumonia in guinea pigs.
@nl
P2093
P2860
P356
P1476
Susceptibility of Legionella p ...... ella pneumonia in guinea pigs.
@en
P2093
Nagasawa M
Nakazato H
Sawatari K
Suzuyama Y
Tomonaga A
P2860
P356
10.1128/AAC.28.1.15
P407
P577
1985-07-01T00:00:00Z